Open and Recruiting
Clinical Trials

• 

  A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer

  Study Details | NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | ClinicalTrials.gov

  • Sponsor

    AstraZeneca

  • Trial ID

    NCT07192614

  • Study Url

    https://clinicaltrials.gov/study/NCT07192614?term=NCT07192614&rank=1

  • Cancer Type

    Prostate Cancer

  • Status

    Recruiting

  Brief Summary

  This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).

• 

  A Phase 1 First-in-human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

  Study Details | NCT06997029 | A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | ClinicalTrials.gov

  • Sponsor

    Bristol-Myers Squibb

  • Trial ID

    NCT06997029

  • Study Url

    https://clinicaltrials.gov/study/NCT06997029?term=NCT06997029&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer　

• 

  A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors

  Study Details | NCT06625593 | A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | ClinicalTrials.gov

  • Sponsor

    BeOne Medicines, formerly BeiGene

  • Trial ID

    NCT06625593

  • Study Details

    A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT06625593?term=BG-C137&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Preparing

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ZW251 in Patients with Advanced Solid Tumors

  https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Sponsor

    Zymeworks

  • Trial ID

    NCT07164313

  • Study Details

    A Study of ZW251 in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT07164313?term=ZW251&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  A First-In-Human, Phase 1, Open-Label, Multicenter Study of ZW251, a Novel Glypican-3 Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors, Including Hepatocellular Carcinoma

• 

  A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

  Study Details | NCT07213609 | A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | ClinicalTrials.gov

  • Sponsor

    GlaxoSmithKline（GSK）

  • Trial ID

    NCT07213609

  • Study Url

    https://clinicaltrials.gov/study/NCT07213609?term=GSK5460025&rank=1

  • Cancer Type

    Advanced solid tumors

  • Status

    Recruiting

  Brief Summary

  The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.

• 

  First-in-Human Phase 1 Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

  • Sponsor

    Boehringer Ingelheim

  • Trial ID

    NCT04958239

  • Study Details

    An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Study Url

    https://clinicaltrials.gov/study/NCT04958239

  • Cancer Type

    Advanced cancer (solid tumors) and head and neck cancer

  • Status

    Preparing

  Brief Summary

  This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer.
  
  In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein.
  
  BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time.

• 

  First-in-Human Study of STX-478 (LY4064809) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  https://clinicaltrials.gov/study/NCT05768139?term=STX-478&rank=2

  • Sponsor

    Eli Lilly / Scorpion Therapeutics, Inc.

  • Trial ID

    NCT05768139

  • Study Details

    First-in-Human Study of STX-478 (LY4064809) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Study Url

    https://clinicaltrials.gov/study/NCT05768139?term=STX-478&rank=2

  • Cancer Type

    Advanced solid tumors with P13Ka mutations, HR+ breast cancer

  • Status

    Preparing

  Brief Summary

  This study is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer.

• 

  A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

  This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

  • Sponsor

    Chugai Pharma USA, Inc.

  • Trial ID

    NCT05907980

  • Study Details

    A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid Tumors

  • Cancer Type

    Advanced Solid Tumors

  • Status

    Preparing

  Brief Summary

  This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.

• 

  A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With ABBV-514 as a Single Agent and in Combination With Budigalimab

  • Sponsor

    AbbVie

  • Trial ID

    NCT05005403

  • Study Details

    Study Details | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Budigalimab | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT05005403?intr=ABBV-514&rank=1

  • Cancer Type

    Advanced or Metastatic Solid Tumors

  • Status

    Recruiting

  Brief Summary

  The purpose of this study is to assess adverse events and pharmacokinetics of ABBV-514 as a monotherapy and in combination with Budigalimab. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of ABBV-514 will be explored. Each treatment arm receives a different dose of ABBV-514 in monotherapy and in combination with Budigalimab.

• 

  A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

  • Sponsor

    AbbVie

  • Trial ID

    NCT06858813

  • Study Details

    Study Details | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | ClinicalTrials.gov

  • Study Url

    https://clinicaltrials.gov/study/NCT06858813?term=ABBV-324&rank=1

  • Cancer Type

    Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

  • Status

    Recruiting

  Brief Summary

  ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period.
  In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of ABBV-324 until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will receive ABBV-324, or a comparator of oral lenvatinib.

For more information on phase one cancer
clinical trials,get in contact our team

Contact